BC Drug Decriminalization Cut Possession Encounters by 39% but Left Overdose Deaths Unchanged

When British Columbia became the first Canadian province to decriminalize the possession of small amounts of certain illegal drugs in January 2023, policymakers hoped the move would help stem a devastating toll of overdose deaths by lowering the fear and stigma that drive people to use drugs alone and avoid treatment. A new study published in the Canadian Medical Association Journal offers the most comprehensive assessment yet of what that experiment actually achieved — and what it did not. The research, a population-level time-series analysis led by Dr. Daniel Myran of North York General Hospital and the University of Toronto, found that decriminalization was associated with a dramatic 39 percent drop in police encounters for drug possession, yet produced no detectable change in drug toxicity deaths or drug-related hospitalizations.

The policy itself was a carefully bounded one. Rather than removing criminal penalties for all drug possession, the Government of British Columbia introduced a time-limited initiative that decriminalized possession of up to 2.5 grams of opioids, cocaine, methamphetamine, and methylenedioxymethamphetamine, commonly known as MDMA or ecstasy. The rationale was grounded in public health reasoning: criminal penalties, proponents argued, discourage people who use drugs from seeking help, push consumption into hidden and solitary settings, and burden individuals with criminal records that compound the harms of substance use. By removing the threat of arrest for small quantities, the province aimed to reduce overdose deaths and increase engagement with treatment and support services.

The policy landscape shifted again in May 2024, when, amid public concern about open drug use and public safety, the government partially recriminalized possession in most public spaces while leaving it decriminalized in designated spaces. Then, in January 2026, the province opted not to renew the decriminalization initiative at all. As Dr. Myran and his coauthors note, these regulatory shifts — the initial decriminalization followed by partial recriminalization — created a natural opportunity to evaluate how changes in drug law enforcement ripple through drug-related health and crime outcomes over time.

To capture those effects, the researchers examined a five-year window running from August 2020 to March 2025, comparing changes in British Columbia against other parts of Canada before and after each policy transition. The scale of the data is striking. Over the study period, the analysis encompassed 97,630 instances of police encounters for drug possession, 75,485 encounters for drug trafficking, 161,278 opioid-related hospitalizations, and 113,747 stimulant-related hospitalizations across Canada, along with 29,730 deaths from drug toxicity in British Columbia, Ontario, and Alberta. By benchmarking British Columbia against comparable jurisdictions that did not change their drug laws, the study design sought to isolate the specific signal of decriminalization from the noise of broader trends.

The headline finding concerns policing. Decriminalization in British Columbia was associated with a 39 percent decrease in police encounters for drug possession — a substantial reduction that returned to pre-decriminalization levels after the partial recriminalization took effect. In other words, the law change did exactly what it was designed to do on the enforcement side: it meaningfully reduced the criminalization of people caught with small amounts of drugs, and when the law was partially reversed, police activity reverted accordingly. This tight coupling between legal status and police behavior suggests that the policy lever operated largely as intended in the criminal justice domain.

The health outcomes tell a more sobering story. Decriminalization was not associated with any measurable change in drug-related hospitalizations or overdose deaths. For a policy whose central justification was reducing overdose mortality, the absence of an observable effect on deaths is a significant result. It indicates that removing criminal penalties for possession, by itself, did not translate into fewer people dying from an increasingly toxic drug supply or fewer people being hospitalized for opioid- and stimulant-related harms during the study period.

Intriguingly, the partial recriminalization period did align with declines in both drug-related hospitalizations and overdose deaths in British Columbia. But the researchers caution against reading this as evidence that recriminalization improved health outcomes. Similar declines occurred across the rest of Canada during the same period, suggesting that broader national trends — rather than the change in possession laws — likely accounted for the improvements. This kind of parallel movement in comparison jurisdictions is precisely what a well-designed time-series analysis is meant to detect, and it prevented the authors from attributing the health gains to the policy reversal.

Dr. Myran summarized the implications bluntly. The findings, he said, reinforce that British Columbia’s temporary decriminalization achieved its intended effect of reducing the criminalization of drug possession among people who use drugs. At the same time, the absence of changes in overdose outcomes highlights that there are no simple solutions to the overdose crisis in Canada, and that other factors and interventions are urgently needed to improve key health outcomes related to drug use. The study thus separates two questions that are often conflated in public debate: whether decriminalization reduces punitive contact with the criminal justice system, and whether it directly saves lives.

Study coauthor Adrienne Gaudreault of Dalhousie University’s Faculty of Medicine in Halifax emphasized that the enforcement findings still matter. Decriminalization was intended to reduce the harms associated with criminalizing people who use drugs, she noted, and the findings suggest it meaningfully reduced police-reported possession incidents. But, she added, changing possession laws alone cannot make an unpredictable and highly toxic drug supply safer. In her view, decriminalization should be understood as one component of a comprehensive public health response that must also address the toxicity of the drug supply itself — a supply that has driven overdose deaths to catastrophic levels across Canada in recent years.

A related commentary in the same journal, authored by Dr. Alexis Crabtree of the British Columbia Centre for Disease Control and the University of British Columbia’s School of Population and Public Health, frames the lesson in systems terms. Decriminalization, the commentary argues, may be best understood as a complex systems intervention, with myriad effects — and possible unintended consequences — emerging from interactions across institutions and sectors. The lesson from British Columbia, according to the commentary, is not that decriminalization is irrelevant, but that such policies must be supported within prepared, trusted, and adequately resourced systems. Taken together, the study and commentary suggest that the province’s experiment delivered a clear verdict on one front — police encounters fell sharply and reversed with recriminalization — while underscoring that the overdose crisis demands interventions that reach beyond the criminal law, from safer supply measures to expanded treatment, if the goal of reducing drug toxicity deaths is to be achieved.

Subject of Research: Population-level effects of drug decriminalization and partial recriminalization on drug-related crime and health outcomes in British Columbia

Article Title: Drug decriminalization in BC reduced police encounters for drug possession, with no changes in drug-related deaths

Article References: Drug decriminalization in BC reduced police encounters for drug possession, with no changes in drug-related deaths. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: drug decriminalization, British Columbia, opioid crisis, drug toxicity deaths, police encounters, drug possession, public health policy, time-series analysis, CMAJ, harm reduction, recriminalization, substance use